Condition

Hormone Refractory Prostate Cancer

ClinicalTrials.gov condition label

Clinical trials35
Recruiting1
Common interventions25
Lead sponsors shown15

Clinical trials

35 shown
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid TumorsNCT07705334 · 2026-06-24
RECRUITING
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer TreatmentNCT02955082 · 2017-05-25
ACTIVE_NOT_RECRUITING
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate CancerNCT02867345 · 2016-11-01
WITHDRAWN
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer PatientsNCT02691975 · 2016-04-12
UNKNOWN
Molecular Phenotype Changes and Personalized Treatment for CRPCNCT02208583 · 2014-06-01
UNKNOWN
Dovitinib(TKI258) in Patients With Castration-resistant Prostate CancerNCT01741116 · 2012-11-01
COMPLETED
Study of Weekly Cabazitaxel for Advanced Prostate CancerNCT01518283 · 2012-05-01
COMPLETED
Radiotherapy vs Observation for CRPCNCT01590498 · 2012-05-01
UNKNOWN
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerNCT01487863 · 2011-12-01
COMPLETED
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With DocetaxelNCT01260688 · 2010-10-01
COMPLETED
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)NCT01194960 · 2010-08-01
TERMINATED
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate CancerNCT01215799 · 2010-08-01
COMPLETED
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)NCT01083615 · 2010-03-01
TERMINATED
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate CancerNCT00928252 · 2009-06-01
COMPLETED
RNActive®-Derived Therapeutic VaccineNCT00906243 · 2009-05-01
TERMINATED
Biomarker Study for Sunitinib and Docetaxel in Prostate CancerNCT00795171 · 2008-11-01
UNKNOWN
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesNCT00699751 · 2008-06-12
COMPLETED
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate CancerNCT00583024 · 2007-12-01
COMPLETED
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate CancerNCT00525408 · 2007-11-01
TERMINATED
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)NCT00571675 · 2007-10-01
COMPLETED
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate CancerNCT00510718 · 2007-07-23
COMPLETED
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer PatientsNCT00411853 · 2007-06-01
UNKNOWN
ABI-008 Trial in Patients With Hormone-refractory Prostate CancerNCT00477529 · 2007-04-01
COMPLETED
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel ChemotherapyNCT00407251 · 2007-02-01
COMPLETED
A Study of Picoplatin and Docetaxel in Subjects With Prostate CancerNCT00448734 · 2006-06-01
UNKNOWN
Safety of LBH589 Alone and in Combination With IV Docetaxel and PrednisoneNCT00493766 · 2006-05-01
TERMINATED
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPCNCT00313482 · 2006-04-01
TERMINATED
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate CancerNCT00286091 · 2006-01-24
COMPLETED
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate CancerNCT00286806 · 2005-12-01
COMPLETED
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate CancerNCT00629525 · 2005-08-01
COMPLETED
BAY88-8223, Does Response Study in HRPC PatientsNCT00667199 · 2005-05-30
COMPLETED
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving ChemotherapyNCT00133900 · 2004-12-01
UNKNOWN
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy RegimenNCT00069745 · 2003-09-01
COMPLETED
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate CancerNCT00156884 · 2003-08-01
COMPLETED
Study Evaluating the Safety and Tolerability of L-377202NCT00987753 · 1999-03-01
COMPLETED

Common interventions

docetaxelDRUG6PrednisoneDRUG3ABI-008DRUG1abiraterone acetateDRUG1ADENOVIRUS/PSA VACCINEBIOLOGICAL1AT-101DRUG1AT-101, prednisone and docetaxelDRUG1BafetinibDRUG1Best standard of care (BSoC)DRUG1cabazitaxelDRUG1Cabazitaxel 10 mg/m2DRUG1CarboplatinDRUG1cediranib maleateDRUG1cisplatinDRUG1cisplatin & EtoposideDRUG1custirsen sodiumDRUG1CV9103BIOLOGICAL1CyclophosphamideDRUG1dasatinibDRUG1DenosumabBIOLOGICAL1Docetaxel * SunitinibDRUG1Docetaxel & PrednisoneDRUG1DP & Targeted drugsDRUG1EP & Targeted drugsDRUG1Fermented Wheat germ extractDRUG1

Trial status mix

COMPLETED19
UNKNOWN7
TERMINATED6
ACTIVE_NOT_RECRUITING1
RECRUITING1
WITHDRAWN1

Phase mix

PHASE224
PHASE110
PHASE34
NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.